 James Burton
Concepts (377)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 31 | 2023 | 830 | 3.680 |
Why?
| | Hepatitis C | 17 | 2021 | 229 | 2.690 |
Why?
| | Antiviral Agents | 17 | 2021 | 649 | 2.280 |
Why?
| | Hepatitis C, Chronic | 11 | 2021 | 152 | 2.200 |
Why?
| | Ribavirin | 8 | 2015 | 89 | 1.500 |
Why?
| | Hepacivirus | 11 | 2021 | 234 | 0.930 |
Why?
| | Proline | 6 | 2015 | 72 | 0.910 |
Why?
| | Protease Inhibitors | 3 | 2018 | 101 | 0.900 |
Why?
| | Kidney Transplantation | 4 | 2023 | 558 | 0.840 |
Why?
| | Liver Function Tests | 3 | 2022 | 105 | 0.800 |
Why?
| | Liver | 10 | 2023 | 1690 | 0.760 |
Why?
| | Oligopeptides | 5 | 2015 | 248 | 0.730 |
Why?
| | Interferon-alpha | 3 | 2014 | 186 | 0.720 |
Why?
| | Drug Therapy, Combination | 12 | 2018 | 962 | 0.700 |
Why?
| | Patient Selection | 3 | 2020 | 654 | 0.660 |
Why?
| | Polyethylene Glycols | 4 | 2014 | 576 | 0.640 |
Why?
| | Interferons | 4 | 2015 | 152 | 0.630 |
Why?
| | Graft Rejection | 4 | 2018 | 533 | 0.580 |
Why?
| | Living Donors | 7 | 2022 | 324 | 0.560 |
Why?
| | Recurrence | 12 | 2015 | 952 | 0.510 |
Why?
| | Postoperative Complications | 5 | 2022 | 2161 | 0.490 |
Why?
| | Liver Failure | 3 | 2016 | 84 | 0.490 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2022 | 246 | 0.410 |
Why?
| | Immunocompromised Host | 1 | 2013 | 197 | 0.380 |
Why?
| | Viral Nonstructural Proteins | 2 | 2014 | 56 | 0.350 |
Why?
| | Humans | 74 | 2023 | 115613 | 0.350 |
Why?
| | Graft Survival | 4 | 2023 | 480 | 0.340 |
Why?
| | Tissue Donors | 4 | 2021 | 331 | 0.330 |
Why?
| | Middle Aged | 35 | 2022 | 27014 | 0.330 |
Why?
| | Home Care Services, Hospital-Based | 2 | 1999 | 11 | 0.320 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2008 | 342 | 0.320 |
Why?
| | Decision Support Techniques | 2 | 2018 | 353 | 0.310 |
Why?
| | Esophageal and Gastric Varices | 1 | 2007 | 33 | 0.290 |
Why?
| | Acute Disease | 7 | 2008 | 914 | 0.290 |
Why?
| | Simeprevir | 2 | 2018 | 9 | 0.280 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2578 | 0.270 |
Why?
| | Tissue and Organ Procurement | 2 | 2023 | 243 | 0.270 |
Why?
| | Health Services for the Aged | 5 | 2000 | 70 | 0.260 |
Why?
| | Liver Cirrhosis | 3 | 2015 | 238 | 0.250 |
Why?
| | Reproducibility of Results | 5 | 2022 | 2800 | 0.250 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2008 | 965 | 0.250 |
Why?
| | United States | 17 | 2023 | 12297 | 0.240 |
Why?
| | Geriatrics | 7 | 2000 | 69 | 0.240 |
Why?
| | Cholates | 2 | 2022 | 2 | 0.240 |
Why?
| | Male | 41 | 2021 | 55968 | 0.240 |
Why?
| | Health Care Rationing | 1 | 2004 | 47 | 0.240 |
Why?
| | Home Care Services | 3 | 1997 | 226 | 0.230 |
Why?
| | Aged | 29 | 2018 | 19255 | 0.230 |
Why?
| | Solitary Kidney | 1 | 2023 | 8 | 0.230 |
Why?
| | Viremia | 3 | 2021 | 122 | 0.230 |
Why?
| | Treatment Outcome | 15 | 2022 | 9159 | 0.220 |
Why?
| | Cecal Neoplasms | 1 | 2003 | 1 | 0.220 |
Why?
| | Jejunoileal Bypass | 1 | 2003 | 1 | 0.220 |
Why?
| | Liver Diseases | 1 | 2006 | 263 | 0.220 |
Why?
| | Reoperation | 4 | 2007 | 525 | 0.220 |
Why?
| | Female | 39 | 2021 | 59932 | 0.220 |
Why?
| | Cholangitis | 1 | 2022 | 20 | 0.200 |
Why?
| | Transplant Recipients | 2 | 2021 | 143 | 0.200 |
Why?
| | Forecasting | 3 | 2014 | 333 | 0.190 |
Why?
| | Recombinant Proteins | 4 | 2014 | 1243 | 0.190 |
Why?
| | Cholangitis, Sclerosing | 1 | 2022 | 74 | 0.190 |
Why?
| | Liver Circulation | 1 | 2021 | 21 | 0.190 |
Why?
| | Colonoscopy | 1 | 2003 | 204 | 0.190 |
Why?
| | Adult | 21 | 2021 | 30726 | 0.190 |
Why?
| | Nursing Homes | 2 | 1994 | 136 | 0.190 |
Why?
| | Carbon Isotopes | 1 | 2021 | 110 | 0.180 |
Why?
| | Famous Persons | 1 | 2000 | 6 | 0.180 |
Why?
| | Deuterium | 1 | 2021 | 78 | 0.180 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2020 | 29 | 0.180 |
Why?
| | Healthy Volunteers | 1 | 2021 | 192 | 0.170 |
Why?
| | Sofosbuvir | 2 | 2021 | 54 | 0.170 |
Why?
| | Kidney | 3 | 2023 | 1207 | 0.170 |
Why?
| | Blood Coagulation Disorders | 1 | 2022 | 196 | 0.170 |
Why?
| | Allografts | 1 | 2020 | 127 | 0.170 |
Why?
| | Donor Selection | 1 | 2020 | 73 | 0.170 |
Why?
| | Carbamates | 2 | 2021 | 35 | 0.170 |
Why?
| | Reference Values | 1 | 2021 | 744 | 0.170 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 96 | 0.160 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 607 | 0.160 |
Why?
| | Cohort Studies | 6 | 2018 | 4945 | 0.160 |
Why?
| | Practice Patterns, Physicians' | 2 | 2005 | 1180 | 0.160 |
Why?
| | Biopsy | 2 | 2020 | 1056 | 0.150 |
Why?
| | Hepatitis, Autoimmune | 1 | 2018 | 32 | 0.150 |
Why?
| | Physician-Patient Relations | 3 | 2000 | 465 | 0.150 |
Why?
| | Geriatric Assessment | 2 | 1997 | 176 | 0.150 |
Why?
| | RNA, Viral | 4 | 2015 | 565 | 0.150 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2018 | 29 | 0.150 |
Why?
| | Eligibility Determination | 2 | 1997 | 60 | 0.150 |
Why?
| | Coronary Angiography | 3 | 2020 | 307 | 0.150 |
Why?
| | Consensus | 1 | 2020 | 532 | 0.150 |
Why?
| | Thrombolytic Therapy | 2 | 1997 | 118 | 0.150 |
Why?
| | Leukocyte Count | 1 | 2018 | 294 | 0.150 |
Why?
| | Retrospective Studies | 11 | 2022 | 12608 | 0.140 |
Why?
| | Drug Interactions | 3 | 2013 | 347 | 0.140 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 88 | 0.140 |
Why?
| | Forkhead Transcription Factors | 2 | 2008 | 171 | 0.140 |
Why?
| | HIV Integrase Inhibitors | 1 | 2018 | 63 | 0.140 |
Why?
| | End Stage Liver Disease | 1 | 2018 | 74 | 0.140 |
Why?
| | Family Planning Policy | 1 | 2016 | 1 | 0.140 |
Why?
| | Adenocarcinoma | 1 | 2003 | 799 | 0.140 |
Why?
| | Odds Ratio | 4 | 2015 | 962 | 0.130 |
Why?
| | Health Planning | 1 | 2016 | 46 | 0.130 |
Why?
| | Prognosis | 5 | 2020 | 3339 | 0.130 |
Why?
| | Public Policy | 1 | 2016 | 61 | 0.130 |
Why?
| | Long-Term Care | 1 | 2016 | 76 | 0.130 |
Why?
| | Prospective Studies | 7 | 2021 | 6264 | 0.130 |
Why?
| | Fibrosis | 1 | 2018 | 457 | 0.130 |
Why?
| | Population Dynamics | 1 | 2016 | 128 | 0.130 |
Why?
| | Aortic Valve Insufficiency | 1 | 2015 | 44 | 0.130 |
Why?
| | Young Adult | 7 | 2021 | 10487 | 0.130 |
Why?
| | Time Factors | 10 | 2018 | 6165 | 0.120 |
Why?
| | Macrocyclic Compounds | 1 | 2014 | 9 | 0.120 |
Why?
| | Genotype | 3 | 2015 | 1787 | 0.120 |
Why?
| | Program Evaluation | 1 | 1999 | 836 | 0.120 |
Why?
| | Developing Countries | 1 | 2016 | 240 | 0.120 |
Why?
| | Survival Analysis | 4 | 2018 | 1219 | 0.120 |
Why?
| | Anilides | 1 | 2014 | 67 | 0.120 |
Why?
| | Homes for the Aged | 1 | 1994 | 19 | 0.120 |
Why?
| | Comprehensive Health Care | 1 | 1994 | 19 | 0.120 |
Why?
| | Patient Satisfaction | 1 | 1998 | 585 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2018 | 552 | 0.110 |
Why?
| | Factor Xa Inhibitors | 2 | 2005 | 138 | 0.110 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2015 | 152 | 0.110 |
Why?
| | Follow-Up Studies | 6 | 2016 | 4440 | 0.110 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2013 | 35 | 0.110 |
Why?
| | Transplantation | 1 | 2013 | 23 | 0.110 |
Why?
| | Quality of Life | 4 | 2018 | 2387 | 0.110 |
Why?
| | Myocardial Infarction | 3 | 2005 | 931 | 0.110 |
Why?
| | Pyridazines | 1 | 2013 | 46 | 0.100 |
Why?
| | Multivariate Analysis | 3 | 2015 | 1440 | 0.100 |
Why?
| | Spinal Diseases | 1 | 1993 | 45 | 0.100 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 55 | 0.100 |
Why?
| | Mental Health | 1 | 2018 | 571 | 0.100 |
Why?
| | Aortic Valve Stenosis | 1 | 2015 | 253 | 0.100 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2012 | 49 | 0.100 |
Why?
| | Cholangiocarcinoma | 1 | 2012 | 38 | 0.100 |
Why?
| | Immunosuppressive Agents | 2 | 2013 | 666 | 0.100 |
Why?
| | Bile Duct Neoplasms | 1 | 2012 | 56 | 0.100 |
Why?
| | Postoperative Care | 1 | 2013 | 222 | 0.100 |
Why?
| | Interleukins | 1 | 2013 | 238 | 0.090 |
Why?
| | Hepatic Insufficiency | 1 | 2010 | 4 | 0.090 |
Why?
| | Chemoradiotherapy | 1 | 2012 | 187 | 0.090 |
Why?
| | Preoperative Care | 1 | 2013 | 318 | 0.090 |
Why?
| | Th1 Cells | 2 | 2008 | 125 | 0.090 |
Why?
| | Blood Component Transfusion | 1 | 2011 | 76 | 0.090 |
Why?
| | Aged, 80 and over | 9 | 2015 | 6419 | 0.090 |
Why?
| | Death Certificates | 1 | 1990 | 30 | 0.090 |
Why?
| | Longitudinal Studies | 4 | 2016 | 2420 | 0.090 |
Why?
| | Autopsy | 1 | 1990 | 86 | 0.090 |
Why?
| | Primary Health Care | 2 | 1993 | 1518 | 0.090 |
Why?
| | Nucleosides | 1 | 2009 | 25 | 0.080 |
Why?
| | Myocardial Stunning | 1 | 2009 | 5 | 0.080 |
Why?
| | Uremia | 1 | 2009 | 14 | 0.080 |
Why?
| | Prodrugs | 1 | 2009 | 43 | 0.080 |
Why?
| | RNA | 1 | 2015 | 819 | 0.080 |
Why?
| | Erythrocyte Transfusion | 1 | 2011 | 187 | 0.080 |
Why?
| | MicroRNAs | 1 | 2015 | 607 | 0.080 |
Why?
| | Drug Resistance, Viral | 1 | 2009 | 99 | 0.080 |
Why?
| | Cross Infection | 1 | 2011 | 202 | 0.080 |
Why?
| | Risk Factors | 8 | 2020 | 8699 | 0.080 |
Why?
| | Drug Discovery | 1 | 2009 | 124 | 0.080 |
Why?
| | Vitamin B 12 Deficiency | 1 | 1988 | 74 | 0.080 |
Why?
| | Registries | 1 | 2016 | 1770 | 0.080 |
Why?
| | Biomarkers | 2 | 2015 | 3468 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 1805 | 0.080 |
Why?
| | Urinary Incontinence | 1 | 1988 | 58 | 0.080 |
Why?
| | Thrombelastography | 2 | 2022 | 179 | 0.080 |
Why?
| | Interferon-gamma | 2 | 2008 | 726 | 0.080 |
Why?
| | Patient Readmission | 2 | 2010 | 609 | 0.070 |
Why?
| | Propionates | 2 | 2005 | 33 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2011 | 300 | 0.070 |
Why?
| | Platelet Count | 1 | 2007 | 83 | 0.070 |
Why?
| | Naphthalenes | 2 | 2005 | 39 | 0.070 |
Why?
| | Ventricular Function, Left | 2 | 2009 | 467 | 0.070 |
Why?
| | Likelihood Functions | 1 | 2007 | 128 | 0.070 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2006 | 11 | 0.070 |
Why?
| | Receptors, Interleukin-7 | 1 | 2006 | 25 | 0.070 |
Why?
| | Models, Statistical | 2 | 2015 | 606 | 0.070 |
Why?
| | Viral Load | 2 | 2021 | 405 | 0.070 |
Why?
| | Behavior Therapy | 1 | 1988 | 225 | 0.070 |
Why?
| | ROC Curve | 1 | 2007 | 451 | 0.070 |
Why?
| | Logistic Models | 3 | 2015 | 1856 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2009 | 369 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 1919 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2020 | 1087 | 0.060 |
Why?
| | Heparin | 4 | 2005 | 227 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 941 | 0.060 |
Why?
| | Ambulatory Care | 1 | 1988 | 479 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2005 | 102 | 0.060 |
Why?
| | Chi-Square Distribution | 2 | 2011 | 499 | 0.060 |
Why?
| | Incidence | 2 | 2010 | 2335 | 0.060 |
Why?
| | Treatment Failure | 1 | 2005 | 332 | 0.060 |
Why?
| | Skilled Nursing Facilities | 1 | 1985 | 119 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2009 | 490 | 0.060 |
Why?
| | Reperfusion Injury | 1 | 2006 | 254 | 0.060 |
Why?
| | Hepatitis B Antibodies | 1 | 2003 | 10 | 0.060 |
Why?
| | House Calls | 1 | 1985 | 128 | 0.060 |
Why?
| | Hepatitis B virus | 1 | 2003 | 25 | 0.060 |
Why?
| | Endoscopes, Gastrointestinal | 1 | 2003 | 12 | 0.060 |
Why?
| | Length of Stay | 3 | 2011 | 958 | 0.060 |
Why?
| | Pilot Projects | 3 | 2009 | 1377 | 0.050 |
Why?
| | Continuity of Patient Care | 1 | 1985 | 255 | 0.050 |
Why?
| | Health Care Surveys | 1 | 2005 | 538 | 0.050 |
Why?
| | Aging | 1 | 1993 | 1631 | 0.050 |
Why?
| | Risk Assessment | 4 | 2015 | 2987 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 1718 | 0.050 |
Why?
| | Colectomy | 1 | 2003 | 87 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 14 | 0.050 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2022 | 30 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2003 | 233 | 0.050 |
Why?
| | Plasma | 2 | 2014 | 213 | 0.050 |
Why?
| | Critical Care | 1 | 1985 | 477 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2006 | 693 | 0.050 |
Why?
| | DNA, Viral | 1 | 2003 | 351 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2021 | 44 | 0.050 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2021 | 16 | 0.050 |
Why?
| | Referral and Consultation | 1 | 1985 | 646 | 0.050 |
Why?
| | Sustained Virologic Response | 1 | 2021 | 33 | 0.050 |
Why?
| | Mental Disorders | 1 | 1988 | 902 | 0.050 |
Why?
| | Feasibility Studies | 2 | 2004 | 741 | 0.050 |
Why?
| | Health Planning Councils | 1 | 2000 | 6 | 0.050 |
Why?
| | Thrombosis | 1 | 2004 | 302 | 0.050 |
Why?
| | Government | 1 | 2000 | 10 | 0.050 |
Why?
| | Blood Coagulation | 1 | 2022 | 221 | 0.040 |
Why?
| | Adolescent | 6 | 2015 | 17903 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 182 | 0.040 |
Why?
| | Muscular Atrophy | 1 | 2000 | 74 | 0.040 |
Why?
| | Anticoagulants | 1 | 2004 | 549 | 0.040 |
Why?
| | Baltimore | 1 | 1999 | 43 | 0.040 |
Why?
| | Cardiac Surgical Procedures | 1 | 2004 | 413 | 0.040 |
Why?
| | Specialization | 1 | 2000 | 117 | 0.040 |
Why?
| | Nephrectomy | 1 | 2020 | 150 | 0.040 |
Why?
| | History, 20th Century | 1 | 2000 | 273 | 0.040 |
Why?
| | Hospitals, University | 1 | 1999 | 172 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 724 | 0.040 |
Why?
| | Streptokinase | 2 | 1997 | 11 | 0.040 |
Why?
| | General Surgery | 1 | 2000 | 129 | 0.040 |
Why?
| | Postoperative Period | 2 | 2016 | 292 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 776 | 0.040 |
Why?
| | Withholding Treatment | 1 | 2018 | 69 | 0.040 |
Why?
| | Oxazines | 1 | 2018 | 25 | 0.040 |
Why?
| | Diagnosis-Related Groups | 1 | 1997 | 27 | 0.040 |
Why?
| | Patient Admission | 1 | 1999 | 175 | 0.040 |
Why?
| | Safety | 1 | 1999 | 298 | 0.040 |
Why?
| | Osteoporosis | 1 | 2000 | 227 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 278 | 0.040 |
Why?
| | Cause of Death | 2 | 2007 | 368 | 0.030 |
Why?
| | Pyridones | 1 | 2018 | 125 | 0.030 |
Why?
| | Myocardial Reperfusion Injury | 1 | 1997 | 93 | 0.030 |
Why?
| | Lymphocytes | 1 | 2018 | 344 | 0.030 |
Why?
| | Attitude | 1 | 1998 | 229 | 0.030 |
Why?
| | Data Collection | 1 | 1999 | 636 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 2 | 1997 | 228 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 296 | 0.030 |
Why?
| | China | 1 | 2016 | 163 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 314 | 0.030 |
Why?
| | Phlebotomy | 1 | 2015 | 11 | 0.030 |
Why?
| | Family Characteristics | 1 | 2016 | 153 | 0.030 |
Why?
| | 2-Naphthylamine | 1 | 2014 | 7 | 0.030 |
Why?
| | Population | 1 | 2015 | 28 | 0.030 |
Why?
| | Half-Life | 1 | 2015 | 145 | 0.030 |
Why?
| | Uracil | 1 | 2014 | 31 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 250 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 465 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2014 | 81 | 0.030 |
Why?
| | Social Class | 1 | 2016 | 210 | 0.030 |
Why?
| | North America | 1 | 2015 | 261 | 0.030 |
Why?
| | Biological Assay | 1 | 2015 | 114 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 59 | 0.030 |
Why?
| | Lactams, Macrocyclic | 1 | 2014 | 46 | 0.030 |
Why?
| | Valine | 1 | 2014 | 74 | 0.030 |
Why?
| | Femoral Artery | 1 | 2015 | 167 | 0.030 |
Why?
| | Cadaver | 1 | 2015 | 316 | 0.030 |
Why?
| | Ritonavir | 1 | 2014 | 72 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2015 | 641 | 0.030 |
Why?
| | Frail Elderly | 1 | 1994 | 105 | 0.030 |
Why?
| | Hepatocytes | 1 | 2014 | 197 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2013 | 3023 | 0.030 |
Why?
| | DEAD Box Protein 58 | 1 | 2013 | 8 | 0.030 |
Why?
| | Leukocytes | 1 | 2014 | 281 | 0.030 |
Why?
| | Neutrophils | 1 | 2018 | 1172 | 0.030 |
Why?
| | Cholestasis | 1 | 2015 | 225 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 1998 | 683 | 0.030 |
Why?
| | HIV-1 | 1 | 2018 | 771 | 0.030 |
Why?
| | Nitriles | 1 | 2013 | 152 | 0.030 |
Why?
| | Pain | 1 | 2018 | 712 | 0.030 |
Why?
| | Medicare Part B | 1 | 1991 | 6 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 203 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2265 | 0.020 |
Why?
| | Physical Examination | 1 | 1993 | 222 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 477 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 854 | 0.020 |
Why?
| | Alcoholism | 1 | 2018 | 717 | 0.020 |
Why?
| | Sulfonamides | 1 | 2014 | 447 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2013 | 434 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 347 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 1998 | 990 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 1993 | 217 | 0.020 |
Why?
| | Heart Transplantation | 1 | 1997 | 671 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 1992 | 249 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 1991 | 88 | 0.020 |
Why?
| | Body Weight | 1 | 2015 | 867 | 0.020 |
Why?
| | Phosphorylation | 1 | 2015 | 1571 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 414 | 0.020 |
Why?
| | Research Design | 1 | 2016 | 946 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 1870 | 0.020 |
Why?
| | Anti-Retroviral Agents | 1 | 2012 | 207 | 0.020 |
Why?
| | Neoadjuvant Therapy | 1 | 2012 | 301 | 0.020 |
Why?
| | Erythrocytes | 1 | 2015 | 589 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 376 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1147 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2517 | 0.020 |
Why?
| | Anemia, Pernicious | 1 | 1988 | 9 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1993 | 1357 | 0.020 |
Why?
| | Urinary Incontinence, Stress | 1 | 1988 | 13 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1536 | 0.020 |
Why?
| | Biofeedback, Psychology | 1 | 1988 | 25 | 0.020 |
Why?
| | Fibrinogens, Abnormal | 1 | 2008 | 4 | 0.020 |
Why?
| | CD24 Antigen | 1 | 2008 | 20 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 1988 | 115 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2010 | 414 | 0.020 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 66 | 0.020 |
Why?
| | Societies, Medical | 1 | 1991 | 684 | 0.020 |
Why?
| | Child | 2 | 2021 | 18487 | 0.020 |
Why?
| | Myocardial Contraction | 1 | 2009 | 316 | 0.020 |
Why?
| | Genes, MHC Class II | 1 | 2007 | 69 | 0.020 |
Why?
| | Hospitalization | 1 | 1996 | 1765 | 0.020 |
Why?
| | Nurse Practitioners | 1 | 1988 | 105 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2011 | 779 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 2007 | 146 | 0.020 |
Why?
| | Stroke Volume | 1 | 2009 | 509 | 0.020 |
Why?
| | Internal Medicine | 1 | 1988 | 211 | 0.020 |
Why?
| | Organizational Affiliation | 1 | 1985 | 8 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2008 | 262 | 0.020 |
Why?
| | Dementia | 1 | 1988 | 185 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4438 | 0.020 |
Why?
| | Waiting Lists | 1 | 2007 | 223 | 0.020 |
Why?
| | Pressure Ulcer | 1 | 1985 | 32 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 1985 | 204 | 0.020 |
Why?
| | Ultrasonography | 1 | 2009 | 642 | 0.020 |
Why?
| | Partial Thromboplastin Time | 1 | 2005 | 51 | 0.020 |
Why?
| | Fluid Therapy | 1 | 1985 | 122 | 0.020 |
Why?
| | Alleles | 1 | 2007 | 794 | 0.010 |
Why?
| | Epitopes | 1 | 2006 | 438 | 0.010 |
Why?
| | Immunologic Memory | 1 | 2006 | 314 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2128 | 0.010 |
Why?
| | Pneumonia | 1 | 1990 | 576 | 0.010 |
Why?
| | International Normalized Ratio | 1 | 2004 | 45 | 0.010 |
Why?
| | Intraoperative Care | 1 | 2004 | 36 | 0.010 |
Why?
| | Blood Coagulation Tests | 1 | 2004 | 57 | 0.010 |
Why?
| | Canada | 2 | 1997 | 335 | 0.010 |
Why?
| | HIV Infections | 1 | 2018 | 2473 | 0.010 |
Why?
| | Physician's Role | 1 | 1985 | 199 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2006 | 1083 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 4668 | 0.010 |
Why?
| | Blood Pressure | 1 | 2009 | 1537 | 0.010 |
Why?
| | Drug Monitoring | 1 | 2004 | 184 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 1218 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 560 | 0.010 |
Why?
| | Ischemia | 1 | 2005 | 363 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4116 | 0.010 |
Why?
| | Hemorrhage | 1 | 2005 | 618 | 0.010 |
Why?
| | Foundations | 1 | 2000 | 22 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 1985 | 686 | 0.010 |
Why?
| | Models, Biological | 1 | 2007 | 1646 | 0.010 |
Why?
| | Organizational Objectives | 1 | 2000 | 71 | 0.010 |
Why?
| | Phenotype | 1 | 2006 | 2831 | 0.010 |
Why?
| | Education, Medical | 1 | 2000 | 225 | 0.010 |
Why?
| | Vascular Patency | 1 | 1997 | 97 | 0.010 |
Why?
| | Coronary Circulation | 1 | 1997 | 128 | 0.010 |
Why?
| | Child, Preschool | 1 | 2009 | 9131 | 0.010 |
Why?
| | Interviews as Topic | 1 | 1997 | 597 | 0.010 |
Why?
| | Regression Analysis | 1 | 1997 | 959 | 0.010 |
Why?
| | Institutionalization | 1 | 1992 | 12 | 0.010 |
Why?
| | Survival Rate | 1 | 1997 | 1650 | 0.010 |
Why?
| | Sex Factors | 1 | 1997 | 1737 | 0.010 |
Why?
| | Organizational Policy | 1 | 1991 | 69 | 0.010 |
Why?
|
|
Burton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|